• Profile
Close

Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations

The Journal of Allergy and Clinical Immunology Nov 04, 2017

Vargas-Hernandez A, et al. - In a study sample of patients with Signal Transducer and Activator of Transcription (STAT)1 gain of function (GOF) mutations, researchers assessed the function of natural Killer (NK) cell. They concluded that properly regulated STAT1 signaling is critical for NK cell maturation and function. In this patient population, modulation of elevated STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay